Video

Dr. Agarwal on Cohort 6 Results ​From the COSMIC-021 Trial in mCRPC

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

Neeraj Agarwal, MD, professor of medicine, and director of the Genitourinary Oncology Program, Huntsman Cancer Institute, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​ (mCRPC).

Cohort 6 was one of the original cohorts in the COSMIC-021 trial Eligible patients had to have progressive soft tissue disease, ​but not necessarily prostate-specific antigen progression, says Agarwal. Men with mCRPC often experience aggressive disease.

After seeing encouraging efficacy data, cohort 6 was expanded to include 130 patients, ​explains Agarwal.

At the 2020 ASCO Virtual Scientific Program, an overall response rate of 32% was observed with the combination of cabozantinib (Cabometyx)* and atezolizumab ​(Tecentriq) in 44 men with mCRPC, Agarwal explains. Additionally, 48% of patients experienced stable disease.* The disease control rate was 80%. The median duration of objective response was 8.3 months, Agarwal adds. These data appear* promising. The combination is being evaluated in a​n international phase 3 trial. 

Related Videos
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS